S41467-019-12987-9.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Edinburgh Research Explorer
Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S. -
Adenylyl Cyclase 2 Selectively Regulates IL-6 Expression in Human Bronchial Smooth Muscle Cells Amy Sue Bogard University of Tennessee Health Science Center
University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 12-2013 Adenylyl Cyclase 2 Selectively Regulates IL-6 Expression in Human Bronchial Smooth Muscle Cells Amy Sue Bogard University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Medical Cell Biology Commons, and the Medical Molecular Biology Commons Recommended Citation Bogard, Amy Sue , "Adenylyl Cyclase 2 Selectively Regulates IL-6 Expression in Human Bronchial Smooth Muscle Cells" (2013). Theses and Dissertations (ETD). Paper 330. http://dx.doi.org/10.21007/etd.cghs.2013.0029. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. Adenylyl Cyclase 2 Selectively Regulates IL-6 Expression in Human Bronchial Smooth Muscle Cells Document Type Dissertation Degree Name Doctor of Philosophy (PhD) Program Biomedical Sciences Track Molecular Therapeutics and Cell Signaling Research Advisor Rennolds Ostrom, Ph.D. Committee Elizabeth Fitzpatrick, Ph.D. Edwards Park, Ph.D. Steven Tavalin, Ph.D. Christopher Waters, Ph.D. DOI 10.21007/etd.cghs.2013.0029 Comments Six month embargo expired June 2014 This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/330 Adenylyl Cyclase 2 Selectively Regulates IL-6 Expression in Human Bronchial Smooth Muscle Cells A Dissertation Presented for The Graduate Studies Council The University of Tennessee Health Science Center In Partial Fulfillment Of the Requirements for the Degree Doctor of Philosophy From The University of Tennessee By Amy Sue Bogard December 2013 Copyright © 2013 by Amy Sue Bogard. -
Comprehensive Analysis Reveals Novel Gene Signature in Head and Neck Squamous Cell Carcinoma: Predicting Is Associated with Poor Prognosis in Patients
5892 Original Article Comprehensive analysis reveals novel gene signature in head and neck squamous cell carcinoma: predicting is associated with poor prognosis in patients Yixin Sun1,2#, Quan Zhang1,2#, Lanlin Yao2#, Shuai Wang3, Zhiming Zhang1,2 1Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China; 2School of Medicine, Xiamen University, Xiamen, China; 3State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, China Contributions: (I) Conception and design: Y Sun, Q Zhang; (II) Administrative support: Z Zhang; (III) Provision of study materials or patients: Y Sun, Q Zhang; (IV) Collection and assembly of data: Y Sun, L Yao; (V) Data analysis and interpretation: Y Sun, S Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work. Correspondence to: Zhiming Zhang. Department of Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, China. Email: [email protected]. Background: Head and neck squamous cell carcinoma (HNSC) remains an important public health problem, with classic risk factors being smoking and excessive alcohol consumption and usually has a poor prognosis. Therefore, it is important to explore the underlying mechanisms of tumorigenesis and screen the genes and pathways identified from such studies and their role in pathogenesis. The purpose of this study was to identify genes or signal pathways associated with the development of HNSC. Methods: In this study, we downloaded gene expression profiles of GSE53819 from the Gene Expression Omnibus (GEO) database, including 18 HNSC tissues and 18 normal tissues. -
New Nomenclature Adhesion-Gpcrs April 22, 2015
New nomenclature Adhesion-GPCRs April 22, 2015 Subfamily Gene name Former Protein name Protein name Comments Reference (PMID) gene name (abbreviated) (full out) (eg, restriction to species) I_ADGRL ADGRL1 LPHN1 Latrophilin 1 Latrophilin 1 Davletov, J Biol Chem Latrophilin- (8798521) like CIRL1 Calcium- Krasnoperov, Biochem independent Biophys Res Commun receptor of α- 1996 (8886023) latrotoxin 1 CL1 CIRL/latrophilin 1 Sugita, J Biol Chem 1998 (9830014) LEC2 Lectomedin-2 Hayflick, J Recept Signal Transduct Res 2000 (10994649) CIRL (CG8639) Calcium- D. melanogaster Lloyd, Neuron 2000 independent (10798391) receptor of α- latrotoxin LAT-1 (B0457.1) Latrophilin-1 C. elegans Mastwal and Hedgecock, International C. elegans Meeting 2001 ADGRL2 LPHN2 Latrophilin 2 Latrophilin 2 Matsushita, FEBS Lett 1999 (10025961) CIRL-2 Calcium- Ichtchenko, J Biol Chem independent 1999 (10026162) receptor of α- latrotoxin 2 CL2 CIRL/latrophilin 2 Sugita, J Biol Chem 1998 (9830014) LPHH1 Latrophilin Human White, Oncogene 1998 homologue in (10030676) humans 1 LEC1 Lectomedin-1 Hayflick, J Recept Signal Transduct Res 2000 (10994649) LAT-2 (B0286.2) Latrophilin-2 C. elegans Mastwal and Hedgecock, International C. elegans Meeting 2001 ADGRL3 LPHN3 Latrophilin 3 Latrophilin 3 Matsushita, FEBS Lett 1999, PMID 10025961 CIRL-3 Calcium- Ichtchenko, J Biol Chem independent 1999 (10026162) receptor of α- latrotoxin 3 CL3 CIRL/latrophilin 3 Sugita, J Biol Chem 1998 (9830014) LEC3 Lectomedin-3 Hayflick, J Recept Signal Transduct Res 2000 (10994649) ADGRL4 ELTD1 ETL EGF-TM7- -
Transcriptome Profiling Reveals the Complexity of Pirfenidone Effects in IPF
ERJ Express. Published on August 30, 2018 as doi: 10.1183/13993003.00564-2018 Early View Original article Transcriptome profiling reveals the complexity of pirfenidone effects in IPF Grazyna Kwapiszewska, Anna Gungl, Jochen Wilhelm, Leigh M. Marsh, Helene Thekkekara Puthenparampil, Katharina Sinn, Miroslava Didiasova, Walter Klepetko, Djuro Kosanovic, Ralph T. Schermuly, Lukasz Wujak, Benjamin Weiss, Liliana Schaefer, Marc Schneider, Michael Kreuter, Andrea Olschewski, Werner Seeger, Horst Olschewski, Malgorzata Wygrecka Please cite this article as: Kwapiszewska G, Gungl A, Wilhelm J, et al. Transcriptome profiling reveals the complexity of pirfenidone effects in IPF. Eur Respir J 2018; in press (https://doi.org/10.1183/13993003.00564-2018). This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Copyright ©ERS 2018 Copyright 2018 by the European Respiratory Society. Transcriptome profiling reveals the complexity of pirfenidone effects in IPF Grazyna Kwapiszewska1,2, Anna Gungl2, Jochen Wilhelm3†, Leigh M. Marsh1, Helene Thekkekara Puthenparampil1, Katharina Sinn4, Miroslava Didiasova5, Walter Klepetko4, Djuro Kosanovic3, Ralph T. Schermuly3†, Lukasz Wujak5, Benjamin Weiss6, Liliana Schaefer7, Marc Schneider8†, Michael Kreuter8†, Andrea Olschewski1, -
Mutations in G Protein–Coupled Receptors: Mechanisms, Pathophysiology and Potential Therapeutic Approachess
Supplemental Material can be found at: /content/suppl/2020/11/26/73.1.89.DC1.html 1521-0081/73/1/89–119$35.00 https://doi.org/10.1124/pharmrev.120.000011 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:89–119, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: PAUL INSEL Mutations in G Protein–Coupled Receptors: Mechanisms, Pathophysiology and Potential Therapeutic Approachess Torsten Schöneberg and Ines Liebscher Rudolf Schönheimer Institute of Biochemistry, Molecular Biochemistry, Medical Faculty, Leipzig, Germany Abstract ................................................................................... 90 Significance Statement. .................................................................. 90 I. Introduction . .............................................................................. 90 II. History .................................................................................... 92 III. General Mechanisms of GPCR Pathologies . ................................................ 93 IV. Inactivating Mutations of GPCRs .......................................................... 95 A. Partially Inactivating Mutations—Loss of Basal Activity . ............................... 97 — B. Partially Inactivating Mutations Alteration of Distinct Receptor Functions............. 97 Downloaded from C. The Special Case—Pseudogenization of GPCRs ......................................... 99 V. Activating Mutations in GPCRs—GoF..................................................... -
RT² Profiler PCR Array (384-Well Format) Mouse G Protein Coupled Receptors 384HT
RT² Profiler PCR Array (384-Well Format) Mouse G Protein Coupled Receptors 384HT Cat. no. 330231 PAMM-3009ZE For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Applied Biosystems® models 7900HT (384-well block), Format E ViiA™ 7 (384-well block); Bio-Rad CFX384™ RT² Profiler PCR Array, Roche® LightCycler® 480 (384-well block) Format G Description The Mouse G Protein Coupled Receptors 384HT RT² Profiler™ PCR Array profiles the expression of a comprehensive panel of 370 genes encoding the most important G Protein Coupled Receptors (GPCR). GPCR regulate a number of normal biological processes and play roles in the pathophysiology of many diseases upon dysregulation of their downstream signal transduction activities. As a result, they represent 30 percent of the targets for all current drug development. Developing drug screening assays requires a survey of which GPCR the chosen cell-based model system expresses, to determine not only the expression of the target GPCR, but also related GPCR to assess off-target side effects. Expression of other unrelated GPCR (even orphan receptors whose ligand are unknown) may also correlate with off-target side effects. The ligands that bind and activate the receptors on this array include neurotransmitters and neuropeptides, hormones, chemokines and cytokines, lipid signaling molecules, light-sensitive compounds, and odorants and pheromones. The normal biological processes regulated by GPCR include, but are not limited to, behavioral and mood regulation (serotonin, dopamine, GABA, glutamate, and other neurotransmitter receptors), autonomic (sympathetic and parasympathetic) nervous system transmission (blood pressure, heart rate, and digestive processes via hormone receptors), inflammation and immune system regulation (chemokine receptors, histamine receptors), vision (opsins like rhodopsin), and smell (olfactory receptors for odorants and vomeronasal receptors for pheromones). -
Investigating the Roles of Neurogenin 3 in Human Pancreas and Intestine
University of Cincinnati March 2, 2016 Investigating the roles of Neurogenin 3 in human pancreas and intestine development and disease. A dissertation submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate Program in Molecular and Developmental Biology of the College of Medicine by Patrick Sean McGrath Bachelor of Science, Colorado State University, May 2009 Committee Chair: James M. Wells, Ph.D. Brian Gebelein, Ph.D. Michael A. Helmrath, MD, MS Stacey S. Huppert, Ph.D. Aaron M. Zorn, Ph.D. Summary The incidence of diabetes mellitus, a disease defined by the inability to properly regulate glucose, is increasing at an alarming rate and affects an estimated 26 million people in the U.S. creating an economic cost of $245 billion per year (American Diabetes, 2013). Glucose homeostasis is regulated through a complex interplay of hormones produced by both the pancreatic and intestinal endocrine systems. Neurogenin 3 is a basic helix-loop-helix (bHLH) transcription factor which acts as a “master regulator” of endocrine cell specification. Mouse studies have shown Neurog3 to be necessary and sufficient for the formation of all endocrine lineages in both the pancreas and intestine. Human patients harboring NEUROG3 mutations have a complete loss of intestinal endocrine cells, but surprisingly retain at least some endocrine pancreas function, calling into question whether NEUROG3 is required for human endocrine pancreas development. To test this directly, we generated human embryonic stem cell (hESC) lines where both alleles of NEUROG3 were disrupted using CRISPR/Cas9-mediated gene targeting. -
Platelet Transcriptome Yields Progressive Markers in Chronic
bioRxiv preprint doi: https://doi.org/10.1101/2021.03.12.435190; this version posted August 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Platelet transcriptome yields progressive markers in chronic 2 myeloproliferative neoplasms and identifies putative targets of therapy 3 4 Zhu Shen1, Wenfei Du1, Cecelia Perkins2, Lenn Fechter2, Vanita Natu3, Holden Maecker4, Jesse Rowley5, 5 Jason Gotlib2,6,8, James Zehnder2,6,7,8, and Anandi Krishnan2,7* 6 7 Affiliations 8 1Department of Statistics, Stanford University, Stanford, CA 9 2Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 10 3Stanford Functional Genomics Facility, Stanford University School of Medicine, Stanford, CA 11 4Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 12 5Department of Internal Medicine, University of Utah, Salt Lake City, UT 13 6Department of Medicine, Stanford University School of Medicine, Stanford, CA 14 7Department of Pathology, Stanford University, Stanford, CA 15 8These authors contributed equally 16 17 *Corresponding Author: 18 Anandi Krishnan, PhD 19 Stanford University, Stanford, CA 20 [email protected] 21 22 23 24 25 Highlights 26 Leveraging two independent and mutually validating MPN patient cohorts, we identify progressive 27 transcriptomic markers that also enable externally validated prediction in MPNs. 28 29 Our platelet RNA-Seq data identifies impaired protein homeostasis as prominent in MPN progression and 30 offers putative targets of therapy. -
[C1C2], Internal
CatNo ProductName CatNo ProductName GTX100001 GPR30 antibody GTX100064 Bcl-2 antibody [N1N2], N-term GTX100003 Melatonin Receptor 1A antibody GTX100065 Chk1 (phospho Ser345) antibody [C1C2], Internal GTX100005 GPR37L1 antibody [C1C2], Internal GTX100067 Chk1antibody [C1C2-3], Internal GTX100008 LHR antibody [C3], C-term GTX100070 Chk1 antibody [C1C2-6], Internal GTX100009 5-HT1B receptor antibody [C1C3] GTX100072 FANCJ antibody [N1N2], N-term GTX100011 GPR146 antibody [N2C1], Internal GTX100077 Rad9 antibody GTX100015 GRPR antibody [C1C2], Internal GTX100078 Rad9 antibody GTX100017 P2Y7 antibody [N3C2], Internal GTX100082 MUS81 antibody GTX100018 EDG7 antibody [N3C2], Internal GTX100084 RecQ1 antibody [N1N2], N-term GTX100024 EDG1 antibody [C2C3], C-term GTX100085 RecQ1 antibody [C1C3] GTX100025 Adenosine A1 Receptor antibody GTX100088 RPA14 antibody [N3C2], Internal GTX100026 TGR5 antibody [C2C3], C-term GTX100090 XAB2 antibody [N1N2], N-term GTX100027 CXCR7 antibody [C1C2], Internal GTX100092 XLF antibody [N3C3] GTX100029 ROR alpha antibody [N2N3] GTX100093 XRCC3 antibody [N1N3] GTX100030 TRHR antibody [C2C3], C-term GTX100094 XRCC4 antibody [N3C3] GTX100031 ABR antibody [C3], C-term GTX100100 DNA ligase IV antibody [N2C2], Internal GTX100032 ACADM antibody GTX100102 NEIL1 antibody [N1C1] GTX100033 AChE antibody [C3], C-term GTX100107 Rad17 antibody [C1C3] GTX100034 alpha Smooth Muscle Actin GTX100113 XRCC2 antibody [N1N3] antibody GTX100035 ACVRL1 antibody [C3], C-term GTX100115 XRCC3 antibody [C1C3] GTX100036 ADAM8 antibody GTX100116 -
Analysis of RHOA Mutations and Their Significance in the Proliferation and Transcriptome of Digestive Tract Cancer Cells
ONCOLOGY LETTERS 22: 735, 2021 Analysis of RHOA mutations and their significance in the proliferation and transcriptome of digestive tract cancer cells NAOKI IKARI1,2, AKIKO SERIZAWA1, ETSUKO TANJI2, MASAKAZU YAMAMOTO1 and TORU FURUKAWA1‑3 1Department of Surgery, Institute of Gastroenterology; 2Institute for Integrated Medical Sciences, Tokyo Women's Medical University, Shinjuku‑ku, Tokyo 162‑8666; 3Department of Investigative Pathology, Tohoku University Graduate School of Medicine, Aoba‑ku, Sendai 980‑8575, Japan Received April 23, 2021; Accepted July 14, 2021 DOI: 10.3892/ol.2021.12996 Abstract. The ras homolog family member A (RHOA) gene showed that the genes associated with small molecule metabolic encodes a member of the Rho family of small GTPases and is process, oxidation‑reduction processes, protein kinase activity, known to function in reorganization of the actin cytoskeleton, transport, and cell junction were commonly downregulated in which is associated with regulation of cell shape, attachment cells whose proliferation was attenuated by the knockdown of and motility. RHOA has been found to be recurrently mutated RHOA. These results suggested that certain RHOA mutations in gastrointestinal cancer; however, the functional signifi‑ may result in upregulation of lnc‑DERA‑1 and genes associated cance of the mutated RHOA protein in digestive tract cancers with cellular metabolism and proliferation in digestive tract remains to be uncovered. The aim of the present study was cancers. to understand the role of mutant RHOA in the proliferation and transcriptome of digestive tract cancer cells. Mutations of Introduction RHOA in one esophageal cancer cell line, OE19, eight gastric cancer cell lines, namely, AGS, GCIY, HGC‑27, KATO III, The ras homolog family member A (RHOA) gene encodes a MKN1, MKN45, SNU16 and SNU719, as well as two colon member of the Rho family of small GTPases and is known cancer cell lines, CCK‑81 and SW948, were determined using to function in reorganization of the actin cytoskeleton, which Sanger sequencing. -
Deletion of Gpr128 Results in Weight Loss and Increased Intestinal Contraction Frequency
Online Submissions: http://www.wjgnet.com/esps/ World J Gastroenterol 2014 January 14; 20(2): 498-508 [email protected] ISSN 1007-9327 (print) ISSN 2219-2840 (online) doi:10.3748/wjg.v20.i2.498 © 2014 Baishideng Publishing Group Co., Limited. All rights reserved. ORIGINAL ARTICLE Deletion of Gpr128 results in weight loss and increased intestinal contraction frequency Ying-Yin Ni, Yan Chen, Shun-Yuan Lu, Bi-Ying Sun, Fang Wang, Xiao-Lin Wu, Su-Ying Dang, Guo-Hua Zhang, Hong-Xin Zhang, Yin Kuang, Jian Fei, Ming-Min Gu, Wei-Fang Rong, Zhu-Gang Wang Ying-Yin Ni, Yan Chen, Fang Wang, Xiao-Lin Wu, Su-Ying mixed 129/BL6 background was generated. The mice Dang, Ming-Min Gu, Zhu-Gang Wang, Department of Medical were genotyped by polymerase chain reaction (PCR) Genetics, E-Institutes of Shanghai Universities, Shanghai Jiao analysis of tail DNA and fed a standard laboratory chow Tong University School of Medicine, Shanghai 200025, China diet. Animals of both sexes were used, and the phe- Shun-Yuan Lu, Hong-Xin Zhang, Zhu-Gang Wang, Research notypes were assessed by histological, biochemical, Centre for Experimental Medicine, Rui Jin Hospital Affiliated molecular and physiological analyses. Semi-quantitative with Shanghai Jiao Tong University School of Medicine, Shang- reverse transcription-PCR and Northern blotting were hai 200025, China Bi-Ying Sun, Guo-Hua Zhang, Wei-Fang Rong, Department used to determine the tissue distribution of Gpr128 of Physiology, Shanghai Jiao Tong University School of Medi- mRNA. Beginning at the age of 4 wk, body weights cine, Shanghai 200025, China were recorded every 4 wk.